Metabolon

Only 15 days left to apply for this quarter’s Metabolon Peak Science Grant!

Could metabolomics help unlock the next breakthrough in your research? Each quarter, we select three finalists and award one winning project a fully funded, Metabolon-supported metabolomics study.

The winning researcher receives:

🔬 Study design and statistical power consultation
🧪 Analysis of up to 100 qualified samples
📊 Access to bioinformatics tools and biological interpretation guidance

Researchers in academia and industry across a range of life science disciplines are encouraged to apply.

And the finalists a 10% credit toward a future Metabolon project too!

Applications close September 30, 2026.

Apply today: https://bit.ly/4wP3M2t

📢 Attending the 11th Annual Meeting of Alliance Against Cancer in Naples?

Tomorrow, Dr. Kristi Buzo of IRCC Candiolo Cancer Institute will present research exploring how targeting WEE1 could help overcome acquired resistance to EGFR blockade in colorectal cancer.

The study features Metabolon metabolomics data, demonstrating how comprehensive biochemical profiling can be incorporated into oncology research to investigate the biology underlying treatment resistance and response.

🎤 Leveraging replication stress through WEE1 inhibition to overcome acquired resistance to EGFR blockade in colorectal cancer

📅 September 11
🕝 14:40
📍 Auditorium

If you’re attending , add this presentation to your agenda to see metabolomics in action in colorectal cancer research.

Attending and curious about Metabolon Verus™?

Tomorrow, Heino Heyman, Director of Global Field Metabolomic Sciences at Metabolon, will take the stage to share the story behind Metabolon Verus™ and the data demonstrating its performance across independent laboratories.

📢 One Kit. Multiple Labs. Reproducible Biochemistry. Now in Your Lab.
📅 September 10
🕛 12:00 PM
📍 MANA 2026 | UC Davis

Join Heino to see how a standardized metabolomics workflow can deliver reproducible biochemistry across laboratories, and bring that capability directly into your lab.

Commercial orders for Metabolon Verus™ are now open, with shipping beginning October 1!

Metabolon Verus™ brings a standardized, end-to-end untargeted metabolomics workflow directly into your lab, helping you generate high-quality, reproducible metabolomics data without having to build and optimize a workflow from scratch.

With Metabolon Verus™, labs can:

• Build on 25+ years of Metabolon metabolomics expertise in their own lab
• Generate consistent, high-quality comparable data across sites
• Scale metabolomics more easily
• Access the Integrated Bioinformatics Platform for deeper insights and faster interpretation

And the reproducibility has been put to the test.

A global ring trial across eight independent labs demonstrated 89% metabolite overlap and a 0.91 median correlation with 7-point calibrated quantitative targeted panels, while strongly conserving the underlying biological response.

Combined with our Early Access Program across 10 laboratories in five countries, the results demonstrate what’s possible when metabolomics is designed for reproducibility, scalability, and biological insight from the start.

Bring the power of Metabolon into your lab.
🔗 Order now: https://bit.ly/3UXAxfJ

International availability coming in early 2027.

Metabolon is heading to UC Davis for MANA 2026!

Join us September 8–11 to connect with our team and discover the Metabolon Verus™ Metabolomics Profiling Kit, a standardized, end-to-end solution designed to bring high-quality metabolomics directly into your lab.

With broad metabolite coverage, robust QA/QC, and a standardized end-to-end workflow, Metabolon Verus™ helps researchers generate reliable, reproducible metabolomics data at scale in their own labs.

We’ll also be hosting a lunch presentation featuring insights from our team and the latest in metabolomics research and applications. More details coming soon!

Attending ? Stop by the Metabolon booth to meet our team and discover what’s possible with Metabolon Verus™.

See you in Davis! 👋

🦠 Virus reactivation in acute and long COVID-19

New research published in Nature found frequent reactivation of chronic viruses including EBV, CMV, HSV1 and Anelloviridae in patients hospitalized with COVID-19. Importantly, reactivation wasn't limited to immunosuppressed patients.

By integrating metabolomics with transcriptomics, proteomics and immune profiling, researchers were able to look beyond viral activity itself and uncover the broader biological response.

Distinct metabolic signatures emerged, including changes in amino acid and lipid metabolism, connecting viral reactivation with downstream functional biology.

🔗 Read the study: https://doi.org/10.1038/s41586-026-10740-z

Global health research, particularly for women and infants, comes from populations in high-income countries. That leaves important gaps in understanding, particularly on how environmental exposures shape health across diverse populations.

That's why today we’re proud to announce the successful completion of multiple global health pilot projects funded by the Gates Foundation, advancing research into conditions that disproportionately affect women and infants in low- and middle-income countries.

These projects show how metabolomics, combined with accessible sample collection methods such as dried blood spots, can help bring high-quality biochemistry profiling to more populations and real-world settings.

Better representation means better biology and, ultimately, better opportunities to improve health outcomes worldwide.

Read the full story: https://bit.ly/4c7JFUV